Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-01 rilvegostomig in advanced or metastatic NSCLC
2023-508262-15-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, open-label trial of rilvegostomig in non-small cell lung cancer (NSCLC) (5 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate, Safety and tolerability and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508262-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508262-15-00.